312 results about "Pulmonary artery" patented technology

The exemplified methods and systems facilitate the quantification of cardiac cycle-variability as a metric of signal quality of an acquired signal data set and the rejection, based on that quantification, of said acquired signal data set from one or more subsequent analyses that can predict and / or estimate a metric associated with the presence, non-presence, severity, and / or localization of abnormal cardiovascular conditions or disease, including, for example, but not limited to, coronary artery disease, abnormal left ventricular end-diastolic pressure disease (LVEDP), pulmonary hypertension and subcategories thereof, heart failure (HF), among others as discussed herein. The quantification of levels of cycle-variability assessed noise such as skeletal-muscle-related-signal contamination and muscle-artifact-noise contamination, and other asynchronous-noise contamination in an acquired signal can be subsequently used for the automated rejection of such asynchronous noise from measurements of biophysical signals.

The invention relates to substituted pyrazolo piperidine carboxylic acids, their salts and to processes for their preparation, and also to their use for preparing medicaments for the treatment and / or prophylaxis of diseases, in particular cardiovascular and cardiac diseases, preferably heart failure with reduced and preserved ejection fraction (HFrEF, HFmrEF and HFpEF), hypertension (HTN), peripheral arterial diseases (PAD, PAOD), cardio-renal and kidney diseases, preferably chronic and diabetic kidney disease (CKD and DKD), cardiopulmonary and lung diseases, preferable pulmonary hypertension (PH), and other diseases, preferably neurodegenerative diseases and different forms of dementias, fibrotic diseases, systemic sclerosis (SSc), sickle cell disease (SCD), wound healing disorders such as diabetic foot ulcer (DFU).

The invention discloses a risk assessment method, system and equipment for idiopathic pulmonary arterial hypertension, and belongs to the field of pulmonary arterial hypertension. According to the method, SNP data containing genotypes and effect values, protein marker expression quantity, metabonomics and clinical data are obtained, the SNP effect values are corrected based on linkage imbalance reference information, and PRS is calculated in combination with the genotypes; constructing a protein expression score by utilizing the site effect value and the expression quantity of the pQTL, and fusing the protein expression score with the PRS to form a target PRS; carrying out dimensionality reduction on metabolome data by adopting sparse coding, extracting sparse coefficients of IPAH related metabolic pathways, and converting the sparse coefficients into metabolic pathway scores; converting the clinical indexes into clinical risk scores; based on the clinical parameter distribution target PRS, the metabolic pathway score and the weight coefficient of the clinical risk score, calculating a risk assessment value; and finally, matching the evaluation value with a preset risk threshold value, and outputting a risk evaluation level. And the IPAH risk assessment accuracy of common people is improved.

The embodiment of the invention provides a pulmonary artery image anomaly classification method and device, equipment and a medium. The pulmonary artery image anomaly classification method comprises the steps that a target CT image and a target ultrasonic image of a pulmonary artery are acquired; respectively coding the target CT image and the target ultrasonic image, and respectively extracting first global and local features of the target CT image and second global and local features of the target ultrasonic image after coding; performing weighted fusion on the first global and local features and the second global and local features through a preset multi-head attention mechanism to obtain multi-modal fusion features; performing decoding processing on the multi-modal fusion features, and performing reconstruction after decoding processing to obtain a target fusion image of the pulmonary artery; and performing anomaly classification based on the target fusion image to obtain an anomaly classification result of the pulmonary artery, thereby improving the accuracy of anomaly classification of the pulmonary artery image.

The invention discloses an application of beta-alanine in preparation of a medicine for treating pulmonary arterial hypertension. In-vivo and in-vitro pharmacological experiments prove that beta-alanine can inhibit lactic acid-mediated histone milk acylation modification and hypoxia-induced phenotypic transformation of PASMCs (Polyaspartic Sulfonate Molecules); the hemodynamics and pulmonary artery vascular remodeling of the PAH mouse are improved. The beta-alanine can inhibit phenotypic transformation of PASMCs and reverse pulmonary artery vascular remodeling which is a key pathological change in the pulmonary hypertension generation process, has huge potential in treatment of pulmonary hypertension, and has good application prospects and high clinical application value.

The invention discloses an ultrasonic pulmonary artery segmentation method, system and equipment based on anatomical perception and a medium, belongs to pulmonary artery segmentation in an artificial intelligence technology, and aims to solve the technical problems of low accuracy and poor segmentation integrity of pulmonary artery segmentation. Comprising the steps of sample image acquisition, classification network fine adjustment and feature extraction, initial response diagram generation, pseudo label generation, segmentation network construction and first training, dynamic anatomy constraint iteration training and pulmonary artery real-time segmentation. When a pseudo label is generated, constructing an anatomical perception pseudo label generation module, inputting the initial response graph into the anatomical perception pseudo label generation module, and outputting an initial pseudo label by the anatomical perception pseudo label generation module; and during iterative training, constructing a differentiable anatomical constraint generator, and performing iterative training on the segmentation network by using the differentiable anatomical constraint generator. A rough and sparse initial response graph is converted into a complete, continuous and reasonably dissected initial pseudo-tag through a pseudo-tag generation module for dissecting perception.

A device for regulating blood pressure between a patient's left atrium and right atrium comprises an hourglass-shaped stent comprising a neck region and first and second flared end regions, the neck region disposed between the first and second end regions and configured to engage the fossa ovalis of the patient's atrial septum, and a drug-eluting biodegradable material that biodegrades over time to release a drug that limits tissue overgrowth. The inventive device also may include a biodegradable material that biodegrades to offset flow changes caused by tissue overgrowth. The inventive device may reduce left atrial pressure and left ventricular end diastolic pressure, and may increase cardiac output, increase ejection fraction, relieve pulmonary congestion, and lower pulmonary artery pressure, among other benefits.

The invention provides a self-adaptive control method and device for a double-ventricle auxiliary system. The method comprises the steps that target aortic pressure detected by a first pressure sensor, target left ventricular end diastolic pressure detected by a second pressure sensor, target right atrial pressure detected by a third pressure sensor and target pulmonary artery pressure detected by a fourth pressure sensor are obtained; and determining a strategy for adjusting the left ventricular assist device or the right ventricular assist device according to the target left ventricular end diastolic pressure, the target right ventricular pressure and the target pulmonary arterial pressure when the peripheral perfusion of the target user is insufficient or the lung is over-perfused. The pressure sensors are arranged to detect the pressure of the inlets and the outlets of the left ventricular assist device and the right ventricular assist device, whether adverse events such as peripheral insufficiency or pulmonary hyperperfusion occur to a user or not is judged according to the detected pressure, and then the adverse events are relieved or even solved by adjusting the rotating speeds of the left ventricular assist device and the right ventricular assist device. And the safety of the user is greatly improved.

Disclosed herein are kits and methods for treating pulmonary arterial hypertension (PAH), comprising administering to a subject in need thereof: •a therapeutically effective amount of a tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof; and•a therapeutically effective amount of a dimeric fusion protein comprising: •the extracellular domain of the activin type 2A (ACTR IIA) or the activin type 2B receptor (ACTR IIB); and the Fc domain of human immunoglobulin G1 (IgG1). In some embodiments, the tyrosine kinase inhibitor is Seralutinib or a pharmaceutically acceptable salt thereof and the fusion protein is Sotatercept.

In some aspects, the present disclosure relates to compositions and methods comprising ActRII polypeptides for treating, preventing, or reducing the rate of progression and / or severity of postcapillary pulmonary hypertension (PcPH), particularly for treating, preventing, or reducing the rate of progression and / or severity of one or more PcPH-related complications. ActRII polypeptides may include polypeptides including any naturally occurring polypeptide of an ActRII family member, and any variant thereof (including mutants, fragments, fusions, and peptidomimetic forms) that retain useful activity.

The invention discloses a blood leakage rate measuring device and method and a clinical actual blood flow obtaining method. The blood leakage rate measuring device comprises a right heart simulator filled with liquid and a pulmonary artery simulator, a second pressure sensor and a first pressure sensor are installed at the bottom in the right heart simulator and the pulmonary artery simulator, the right heart simulator is communicated with the pulmonary artery simulator through a first pipeline and a second pipeline, and an auxiliary pump is installed on the first pipeline. The right heart auxiliary catheter penetrates through the right heart simulator, the valve assembly is arranged in liquid in the right heart simulator, the end cap is arranged in liquid in the pulmonary artery simulator, a second flow sensor is installed on the outer wall of the short tube part between the right heart simulator and the pulmonary artery simulator, and a first flow sensor is installed on the outer wall of the long tube part close to the extracorporeal membrane type cavity. According to the clinical actual blood flow obtaining method, the actual blood flow of the right heart auxiliary catheter can be accurately obtained through the obtained blood leakage rate.

The invention discloses a cryoablation catheter system for pulmonary artery stent internal restenosis, and belongs to the field of medical instruments, the cryoablation catheter system comprises a catheter main body arranged on a guide wire, the catheter main body is provided with a treatment assembly, the treatment assembly is located at the far end of the catheter main body, the catheter main body is provided with a control handle, and the control handle is located at the far end of the catheter main body. The control handle is located at the near end of the catheter body, and the treatment assembly comprises a near-end balloon, a far-end balloon and a freezing balloon. When the near-end balloon and the far-end balloon are simultaneously full, a closed treatment cabin isolated from near-end blood flow and far-end blood flow can be formed in a blood vessel of a target treatment section, the freezing balloon is located in the treatment cabin, the closed treatment cabin thoroughly eliminates the blood flow hot pool effect, cold is prevented from being taken away by the blood flow, and the treatment effect is improved. Freezing energy is intensively acted on a diseased region, so that the ablation efficiency and accuracy are improved; meanwhile, thrombus, tissue debris and whole body blood flow which fall off in the treatment process are isolated, the risk of far-end embolism is reduced from the source, and damage to the blood vessel wall is avoided.

The technology herein provides various embodiments that relate to a method of treating pulmonary hypertension in a subject in need thereof, comprising administering to the subject an effective amount of BX-912 (N-[3-[[5-bromo-4-[2-(1H-imidazol-5-yl)ethylamino]-2-pyrimidinyl]amino]phenyl]pyrrolidine-1-carboxamide).

This paper provides a method for treating pulmonary hypertension with heart failure and preserved ejection fraction (PH-HFpEF). [Solution] To provide a composition and method useful for treating PH-HFpEF, employing the use of levocimendan.

The present invention provides, in part, a novel small molecule PHD inhibitor having a structure according to Formula (A) or a sub-formula thereof: or a pharmaceutically acceptable salt thereof. The compounds provided herein are useful in the treatment of diseases, including heart diseases (e.g., ischemic heart disease, congestive heart failure, and valvular heart disease), lung diseases (e.g., acute lung injury, pulmonary arterial hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), liver diseases (e.g., acute liver failure and liver fibrosis, and cirrhosis), and kidney diseases (e.g., acute liver failure, liver fibrosis, and cirrhosis). Acute kidney injury and chronic kidney disease).

This invention provides a method for treating a pulmonary arterial hypertension with reduced incident of side effect using a controlled release pharmaceutical composition of selexipag or its active metabolite, wherein the controlled release pharmaceutical composition of selexipag or its active metabolite following oral administration with an alcoholic beverage reduces incidence of at least one side effect associated with the selexipag or its active metabolite compared to the immediate-release dosage form comprising the same amount of the selexipag or active metabolite thereof.

The invention relates to a crystal form of a compound shown as a formula I or a pharmaceutically acceptable salt thereof and a preparation method of the crystal form of the compound shown as the formula I or the pharmaceutically acceptable salt thereof. The compound of the formula I or the pharmaceutically acceptable salt thereof is used for treating cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, heart failure, pulmonary arterial hypertension (WHO levels I, II, III, IV), angina pectoris, thrombus, restenosis, myocardial infarction, stroke, cardiac insufficiency, fibrosis, pulmonary hyperplasia, erectile dysfunction, asthma, chronic kidney disease, diabetes, and the like. The composition can be used for treating liver cirrhosis, chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome, acute lung injury, pulmonary fibrosis, cystic fibrosis or interstitial lung disease.

The present disclosure provides a method for preventing or treating pulmonary arterial hypertension in a subject in need thereof, the method comprising administering to the subject an effective amount of 7-dehydrocholesterol, a salt, oxide, metabolite, or derivative thereof.

The application belongs to the technical field of biological detection, and discloses a cardiovascular marker control article and a preparation method thereof. The cardiovascular marker control article comprises a serum matrix, antigens, a preservative and a stabilizer. The antigens include cardiac troponin I antigens, creatine kinase isoenzyme antigens, myoglobin antigens, amino-terminal brain natriuretic peptide precursor antigens, brain natriuretic peptide antigens, D-dimer antigens, heart-type fatty acid-binding protein antigens, myeloperoxidase antigens and lipoprotein phospholipase A2 antigens. The stabilizer includes at least one of D-trehalose, sucrose, glycine, inositol and polyethylene glycol. The cardiovascular marker control article can cover various cardiovascular disease markers, including heart failure, pulmonary embolism, vasculitis and atherosclerosis, myocardial injury, myocardial infarction and the like. The control article can be used as a third-party control article for indoor and inter-laboratory quality control of a cardiovascular disease screening and auxiliary diagnosis measurement system.

The invention relates to a riociguat prodrug as shown in a formula X or pharmaceutically acceptable salt thereof, a preparation method, an intermediate and a pharmaceutical composition thereof. The prodrug takes amino of riociguat as a modification site and is connected through an ester carrier, drug release is triggered by utilizing lung amidase, and lung targeted delivery is realized by adjusting a lipid-water partition coefficient. Pharmacokinetic studies show that the prodrug can significantly improve the drug concentration and total exposure of the lung, reduce the blood concentration of the whole body, and show excellent lung targeting characteristics. The invention also provides a pharmaceutical composition (preferably an inhalation preparation) containing the prodrug, and an application of the prodrug in preparation of drugs for preventing, treating, treating or relieving pulmonary arterial hypertension of patients. .

The invention provides a ventricular elasticity value estimation method and device.The method comprises the steps that a first parameter and a second parameter are obtained, the first parameter comprises at least one of target ventricular pressure, target aortic pressure and target pulmonary arterial pressure of a target user, and the second parameter comprises at least one of the target ventricular pressure, the target aortic pressure and the target pulmonary arterial pressure; the second parameter comprises the pumping flow of the target ventricular assist device and the cardiac cycle of the target user; inputting the first parameter and the second parameter into a target decision model, and outputting a target ventricular volume; and estimating a target ventricular elasticity value according to the ratio of the target ventricular pressure to the target ventricular volume. The ventricular volume of the current user is estimated through the decision model, the estimated ventricular elasticity value is calculated according to the ratio of the ventricular pressure to the ventricular volume, and the ventricular elasticity value of the patient can be accurately predicted in real time without depending on ultrasonic equipment.

The application provides a pulmonary artery tissue-derived cell, an organoid and a construction method and application thereof. The pulmonary artery intimal stripping tissue organoid structure obtained by the preparation method is clear, has consistent cell types as the source tissue, is close to the original tissue, is convenient for researchers to operate, and thus has good practical application value.

The present invention provides, in part, novel small molecule inhibitors of PHD, having a structure according to Formula (I), and sub-formulas thereof: Formula (I) or a pharmaceutically acceptable salt thereof. The compounds provided herein can be useful for treatment or prevention of diseases including heart (e.g. ischemic heart disease, congestive heart failure, and valvular heart disease), lung (e.g., lung inflammation, pneumonia, acute lung injury, pulmonary hypertension, pulmonary fibrosis, and chronic obstructive pulmonary disease), respiratory (e.g.,respiratory infection, acute respiratory distress syndrome), liver (e.g. acute liver failure and liver fibrosis and cirrhosis), and kidney (e.g. acute kidney injury and chronic kidney disease) disease, inflammatory bowel disease (IBD), ischemic reperfusion injury (e.g., stroke), retinopathy of prematurity (ROP), bronchopulmonary dysplasia (BPD), and white matter injury (WMI).

The present disclosure is directed to pharmaceutical compositions comprising a PDE V inhibitor and one or more pharmaceutical excipients or additives wherein the pharmaceutical compositions are in the form of liquid pharmaceutical compositions. The pharmaceutical compositions of the present disclosure are useful for the treatment of diseases or conditions which are treatable by administration of PDE V inhibitor drug such as pulmonary arterial hypertension, erectile dysfunction, etc.

Methods of administering an anti-arrhythmic, such as dofetilide, to a patient in an amount effective for treating a cardiovascular condition are described. The drug can be administered intravenously for at least one hour. A loading dose of 0.1 to 12 μg / kg bodyweight over a duration of up to 60 minutes can be administered and / or a maintenance dose of 0.1 to 10 μg / kg / hr can be administered intravenously over a duration of at least 1 hour, optionally alternatively or in addition wherein the amount of the loading dose and / or the IV maintenance dose is in the range of about ±50% of a maintenance dofetilide dose. The cardiovascular condition can include atrial fibrillation or flutter, ventricular tachycardia, hemodynamically stable or unstable ventricular tachycardia, paroxysmal atrial fibrillation, ventricular fibrillation, paroxysmal supraventricular tachycardia, heart failure, coronary artery disease, or pulmonary artery hypertension. A patient's QT interval and / or a creatinine clearance can be measured, and the effective amount can be selected based on either or both of the QT interval or the creatinine clearance measurements.

The application discloses a method for constructing a 4D FLOW-based hemodynamic evaluation pulmonary embolism prognosis prediction model and application, relates to the medical image technology field, and comprises the following steps: collecting 4D-Flow images of patients who have been diagnosed with pulmonary embolism from medical institutions to obtain image data A; pre-processing the image data A, and dividing the pre-processed image data A into a training set and a verification set according to a proportion; respectively performing imageomic feature extraction, clinical feature extraction and 4D FLOW hemodynamic feature extraction on the training set and the verification set; screening the imageomic features and the clinical features and 4D FLOW hemodynamic detection indexes to obtain key features; and based on the key features, establishing a multi-omics prediction model for pulmonary embolism prognosis prediction, thereby providing a new imaging reference for pulmonary embolism treatment.

Disclosed systems, methods, and computer readable media can diagnose a health condition based on patient time series data. For example, a method for diagnosing a health condition based on patient time series data includes identifying a training set of health records comprising a first set of patient time series data, training a neural network using the training set of health records, and executing the trained neural network model to diagnose a health condition based on a second set of patient time series data. In further examples, the first set of patient time series data and the second set of patient time series data can each comprise electrocardiogram data and the health condition can comprise pulmonary hypertension.

The invention relates to an mRNA (messenger Ribonucleic Acid) medicine and application thereof in treating pulmonary arterial hypertension. In particular, the present invention relates to polynucleotides encoding peptides comprising a BMP9 active molecule and / or an ACTRIIA ligand trapping agent, lipid nanoparticles comprising said polynucleotides, and therapeutic uses thereof.

The present invention relates to methods of treating / preventing abnormal conditions associated with pulmonary arterial hypertension (PAH) and methods of treating PAH in subjects refractory to treatment for PAH, said methods involving administering to the subject of an effective amount of a of Formula (I), wherein R1 is either H or D and wherein D is deuterium, or a pharmaceutically acceptable salt thereof.

The application provides a chest plain CT image lung artery and vein automatic extraction method, and relates to the technical field of CT image processing. The method first acquires lung airway, lung blood vessel and lung external artery and vein data, and performs data preprocessing and unifies layer thickness; then, based on the reconstructed CT scan image, lung blood vessel skeletonization is performed; and a lung internal artery and vein growth algorithm is used to classify the lung blood vessel skeleton; then, the lung artery and vein are reconstructed according to the artery and vein marked by the lung blood vessel skeleton; finally, the classified lung blood vessel is evaluated according to the blood vessel skeleton of the marked lung internal artery and vein and the blood vessel voxel point after the lung internal artery and vein reconstruction. The method uses multiple features to classify the lung internal artery and vein, does not require the imaging mode of the input data, is an automatic algorithm, does not require manual parameter adjustment or seed point setting, has strong generalization ability, and proposes two new evaluation methods, so that the classification effect of the lung artery and vein is checked and evaluated from multiple angles.